Literature DB >> 2476563

Differential effects of triiodothyronine on rat left and right ventricular function and the influence of metoprolol.

W Zierhut1, H G Zimmer.   

Abstract

The influence of triiodothyronine (T3) on right ventricular functional parameters was tested and compared to the alterations induced in the left ventricle. Female Sprague-Dawley rats received daily injections of T3 (0.2 mg/kg s.c.) for 3 days and a constant i.v. infusion of 0.9% NaCl or the beta 1-receptor blocker metoprolol (1 mg/kg/h). The hyperthyroid state after 3 days administration of T3 was characterized by an increase in heart rate and cardiac output and a decrease in the systemic peripheral resistance. However, pulmonary vascular resistance was unchanged. Beta-Receptor blockade reduced heart rate to the control level without affecting the elevation in cardiac output. The T3 group showed a marked increase in right ventricular systolic pressure (RVSP) and mean pulmonary artery pressure, whereas left ventricular systolic pressure (LVSP) and mean aortic pressure were not significantly changed. Metoprolol had no effect on LVSP, and attenuated the increase in RVSP. Furthermore, T3 induced a considerable increase in dP/dtmax in both ventricles, which was reduced nearly to control level by concomitant metoprolol infusion. The T3-induced percentage weight gain of the right ventricular free wall (RV) was more pronounced than that of the left ventricle (LV) as indicated by the significant increase in the RV/LV weight and the RNA/DNA ratios. Metoprolol did not affect significantly the T3-induced left and right ventricular hypertrophy, but attenuated slightly the elevated RV/LV weight ratio. Our results indicate a different action of T3 on systemic and pulmonary circulation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2476563     DOI: 10.1016/0022-2828(89)90827-4

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  8 in total

Review 1.  Some aspects of cardiac heterogeneity.

Authors:  H G Zimmer
Journal:  Basic Res Cardiol       Date:  1994 Mar-Apr       Impact factor: 17.165

2.  Thyroid control of contractile function and calcium handling in neonatal rat heart.

Authors:  F Kolár; E K Seppet; R Vetter; J Procházka; J Grünermel; K Zilmer; B Ostádal
Journal:  Pflugers Arch       Date:  1992-05       Impact factor: 3.657

3.  The expression of mRNA of cytokines and of extracellular matrix proteins in triiodothyronine-treated rat hearts.

Authors:  Barbara Ziegelhöffer-Mihalovicová; Wilfried Briest; Hideo A Baba; Beate Rassler; Heinz-Gerd Zimmer
Journal:  Mol Cell Biochem       Date:  2003-05       Impact factor: 3.396

4.  Energy metabolism response to calcium activation in isolated rat hearts during development and regression of T3-induced hypertrophy.

Authors:  S Lortet; M Heckmann; A Ray; A Rossi; J Aussedat; S Grably; H G Zimmer
Journal:  Mol Cell Biochem       Date:  1995-10-18       Impact factor: 3.396

5.  Effects of triiodothyronine in spontaneously hypertensive rats. Studies on cardiac metabolism, function, and heart weight.

Authors:  M Heckmann; H G Zimmer
Journal:  Basic Res Cardiol       Date:  1992 Jul-Aug       Impact factor: 17.165

6.  Response of the rat heart to catecholamines and thyroid hormones.

Authors:  H G Zimmer; M Irlbeck; C K Kolbeck-Rühmkorff
Journal:  Mol Cell Biochem       Date:  1995 Jun 7-21       Impact factor: 3.396

7.  Longstanding hyperthyroidism is associated with normal or enhanced intrinsic cardiomyocyte function despite decline in global cardiac function.

Authors:  Nathan Y Weltman; Dajun Wang; Rebecca A Redetzke; A Martin Gerdes
Journal:  PLoS One       Date:  2012-10-04       Impact factor: 3.240

8.  The Effect of Sorafenib, Tadalafil and Macitentan Treatments on Thyroxin-Induced Hemodynamic Changes and Cardiac Abnormalities.

Authors:  Nancy S Saad; Kyle Floyd; Amany A E Ahmed; Peter J Mohler; Paul M L Janssen; Mohammad T Elnakish
Journal:  PLoS One       Date:  2016-04-15       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.